E
Emmanuel Ecosse
Researcher at Paris Descartes University
Publications - 38
Citations - 2441
Emmanuel Ecosse is an academic researcher from Paris Descartes University. The author has contributed to research in topics: Population & Cohort study. The author has an hindex of 20, co-authored 38 publications receiving 2161 citations. Previous affiliations of Emmanuel Ecosse include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
The French SF-36 Health Survey: Translation, Cultural Adaptation and Preliminary Psychometric Evaluation
TL;DR: In this paper, the authors report on the main developmental stages and preliminary psychometric assessment of the final French version of the SF-36, using data from a general population survey.
Journal ArticleDOI
Long-Term Mortality after Recombinant Growth Hormone Treatment for Isolated Growth Hormone Deficiency or Childhood Short Stature: Preliminary Report of the French SAGhE Study
Jean-Claude Carel,Emmanuel Ecosse,Fabienne Landier,Djamila Meguellati-Hakkas,Florentia Kaguelidou,Grégoire Rey,Joël Coste +6 more
TL;DR: Mortality rates were increased in this population of adults treated as children with recombinant GH, particularly in those who had received the highest doses, highlighting the need for additional studies of long-term mortality and morbidity after GH treatment in childhood.
Journal ArticleDOI
Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases.
TL;DR: In this article, the authors evaluated the impact of the severity and visibility of neurofibromatosis type 1 on quality of life (QoL) through association with severe complications, impact on cosmetic features, and uncertainty of the effects of the disorder.
Journal ArticleDOI
Adult height and pubertal growth in Turner syndrome after treatment with recombinant growth hormone.
Leandro Soriano-Guillén,Joël Coste,Emmanuel Ecosse,Juliane Léger,Maïté Tauber,Sylvie Cabrol,Marc Nicolino,Raja Brauner,Jean-Louis Chaussain,Jean-Claude Carel +9 more
TL;DR: The results support the early initiation of GH treatment and induction of puberty at a physiological age to achieve optimal AH and suggest that GH should be injected daily, and percutaneous estrogens used.
Journal ArticleDOI
Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry
Jean-Claude Carel,Emmanuel Ecosse,Marc Nicolino,Maïté Tauber,Juliane Léger,Sylvie Cabrol,Irène Bastie-Sigeac,Jean-Louis Chaussain,Joël Coste +8 more
TL;DR: Half the patients treated for idiopathic isolated growth hormone deficiency stop treatment before reaching adult height and achieve adult heights similar to those of patients who complete their treatment, which support the use of growth hormone in such patients.